Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : sciclone pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: Captain Jack who wrote (888)	8/22/2001 8:17:20 PM
From: Oak Tree	Read Replies (1) \| Respond to of 1137

You hit it right on. Some will be successes others wont. The molecule of this year is the bust of the next year. EGFR is a molecule of the year -- the hype molecules never are all they are stacked up to be. P53 went down, NO went down, FGF went down, EGFR is going to go down. I wish I were wrong. The growth factors that have been successes are those that are aimed at helping normal tissues not the ones that attack tumors (the tumors are too smart). Examples of the successes are GCSF and EPO. Take care